Skip to content

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05081245
Enrollment
168
Registered
2021-10-18
Start date
2022-09-13
Completion date
2026-04-17
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

ASD, Autism, Autism Spectrum Disorder, Social Communication

Brief summary

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.

Interventions

Participants will receive ML-004 once daily.

DRUGML-004 Placebo

Participants will receive matching placebo once daily.

Sponsors

MapLight Therapeutics
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Double-blind

Intervention model description

Multi-center, randomized, double-blind, placebo-controlled study

Eligibility

Sex/Gender
ALL
Age
12 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Age 12 to 45 at screening * Has a designated care/study partner who can reliably report on symptoms * Has a diagnosis of Autism Spectrum Disorder (ASD) * Has a body mass index (BMI) 18 through 34 kg/m², inclusive * Full scale IQ (or equivalent) ≥55 score, with adequate verbal fluency, as determined by the Principal Investigator. * Psychoactive medications and adjunctive therapies are stable for 4 weeks prior to screening * Must be able to swallow study medication

Exclusion criteria

* Has Rett syndrome or Child Disintegrative Disorder * Has participated in any other study and received any other investigational medication (other than COVID-19 vaccination) or device within 60 days prior to screening * History of epilepsy without current adequate control, or any seizure in the 6 months preceding screening * History of suicidal ideation or behavior in the past 12 months, or a positive response to C-SSRS questions 4 and/or 5 * Systolic blood pressure ≥140 mmHg (if adult) or \>135 mmHg (if adolescent), or diastolic blood pressure ≥90 (if adult) or \>85 mmHg (if adolescent), or a clinical history of uncontrolled or severe hypertension * If female, is pregnant or lactating

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain ScoreBaseline up to Day 110Change from baseline in the ABI-Social Communication Domain Score will be reported. The ABI is a 62-item questionnaire for reporting the behaviors of subjects (ages: 3 years-adulthood) diagnosed with ASD. The tool is suitable for completion by parents or care/study partners of people with ASD. Each item assesses either quality (from not at all to without help) or frequency (never to very often) of a particular behavior. The Social Communication domain score is the sum of the scores in the social communication domain divided by the number of items in the domain.

Secondary

MeasureTime frameDescription
Change from Baseline in Clinician Global Impression of Improvement (CGI-I)Day 110The CGI-I score is a single-item instrument based on a 7-point scale routinely used in clinical trials to capture the Investigator's global impression of response. The Investigator or designee rates the improvement observed from 1 (very much improved) to 7 (very much worse).
Change from Baseline in Autism Behavior Inventory-Clinician (ABI-C) ScoreBaseline up to Day 110The ABI-Clinician (ABI-C) captures the clinician rating of behaviors of a person with ASD that occurred over the week prior to assessment. It contains 14 items reflecting the core and associated autism behavior domains: Social Communication, Restrictive Behaviors, Mood and Anxiety, Self Regulation, and Challenging Behavior. Each item is rated on a 7-point scale from 1 (none; no symptoms present) to 7 (very severe; persistent interference with function or adaptation).
Change from Baseline in Aberrant Behavior Checklist 2-Irritability (ABC-I) Subscale ScoreBaseline up to Day 110The ABC is a parent- or care/study partner-reported behavior rating assessment with five domains and 58 items, each rated on a 0 (not at all a problem) to 3 (the problem is severe in degree) scale. The irritability domain consists of 15 items.
Change from baseline in the Clinician Global Impression of Severity (CGI-S) ScoreBaseline up to Day 110The CGI-S is a global assessment of the clinician-rater's impression of the severity of the participant's illness. It is rated on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill).
Change from baseline in the ABI Repetitive/Restrictive Behavior Domain ScoreBaseline up to Day 110Each item on the ABI-Repetitive/Restrictive Behavior Domain is rated by frequency (never to very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.
Change from baseline in the ABI Mood and Anxiety Domain ScoreBaseline up to Day 110Each item on the ABI- Mood and Anxiety Domain is rated by frequency (never to very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.
Change from baseline in the ABI Challenging Behavior Domain ScoreBaseline up to Day 110Each item on the ABI- Challenging Behavior Domain is rated by frequency (never to very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.
Change from baseline in the ABI Self-regulation Domain ScoreBaseline up to Day 110Each item on the ABI- Self-regulation Domain is rated by frequency (never to very often). The domain score is the sum of all domain items scores divided by the number of items in the domain.
Change from baseline in the ABI-Short Form (ABI-S) ScoreBaseline up to Day 110The ABI-S is a 24-item short version of the ABI, containing items from each of the five domains. The domain score for each domain is calculated as the sum of scores all domain items divided by the number of items in the domain.
Change from baseline in the ABC-Social Withdrawal (ABC-SW) Subscale ScoreBaseline up to Day 110The ABC-SW subscale consists of 16 items of the ABC-2 rated from 0 (not at all a problem) to 3 (the problem is severe in degree).
Change from baseline in the Social Responsiveness Scale 2 (SRS-2) ScoreBaseline up to Day 110The SRS-2 consists of 65 items across 5 subscales. Responses range from 1 (not true) to 4 (almost always true).
Change from baseline in the Vineland-3 (Domain Level Version) Score: total of Communication, Socialization, and Maladaptive behavior domainsBaseline up to Day 110The Vineland-3 Domain Level Version contains 5 domains. Responses on each item are rated from 0 (never) to 2 (usually).

Countries

Australia, Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026